Name: Meloxicam
Brand: Selleck Chemicals
SKU: S1734
Availability: InStock
Rating: 5 (5 reviews)

Jump to

Quality Control

Batch: S173401 DMSO]30 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.91%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

99.91

Related Targets	Adrenergic Receptor AChR 5-HT Receptor Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other COX Inhibitors	NS-398 (NS398) Paeoniflorin (NSC 178886) Xanthohumol Lumiracoxib Bufexamac Ginsenoside Rd Etoricoxib Oroxin B Nimesulide (-)-Epicatechin gallate

Solubility

In vitro
Batch:

DMSO : 30 mg/mL (85.37 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.000mg/ml (2.85mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.200mg/ml (0.57mM)	Taking the 1 mL working solution as an example, add 50 μL of 4 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	351.4	Formula	C₁₄H₁₃N₃O₄S₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	71125-38-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	COX
In vitro	Meloxicam significantly reduces HCA-7 and Moser-S colony size. This compound significantly inhibits HCA-7 colony and tumor growth but has no effect on the growth of the COX-2 negative HCT-116 cells. It inhibits PGE(2) production, proliferation and invasiveness especially in MG-63 cells, which express relatively high levels of COX-2. This chemical causes apoptosis and upregulates Bax mRNA and protein in MG-63 cell culture.
In vivo	Meloxicam suppresses LM-8 tumor growth and lung metastasis in vivo mouse model. This compound causes a significant reduction in lameness at post injection hour (PIH) 8 and 24 and tends to reduce effusion in horse. It significantly suppresses synovial fluid (SF) prostaglandin E2 and substance P release at PIH 8 and bradykinin at PIH 24 compared to placebo treatment in horse. This agent reduces general MMP activity at PIH 8 and 24 in horse. This compound- or flunixin-treated horses has improved postoperative pain scores and clinical variables, compared with SS-treated horses. It results in high numbers of neutrophils in ischemia-injured tissue of horse. Its administration significantly suppresses PGE2 concentrations in blood and synovial fluid at days 7 and 21, but has no effect on concentrations of TXB2 in blood or PGE2 in gastric mucosa in dogs.
References	[1] https://pubmed.ncbi.nlm.nih.gov/9886578/ [2] https://pubmed.ncbi.nlm.nih.gov/16219634/ [3] https://pubmed.ncbi.nlm.nih.gov/19927589/ [4] https://pubmed.ncbi.nlm.nih.gov/17542694/ [5] https://pubmed.ncbi.nlm.nih.gov/12428662/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-10-24)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07158476	RECRUITING	ACL Surgery; Pain Management	St. Louis University	2025-10-21	PHASE4
NCT07430085	NOT_YET_RECRUITING	Periarticular Block; Osteoarthritis (OA); Osteoarthritis (OA) of the Knee; Pain After Surgery; Knee Arthroplasty, Total	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	2026-07-31	PHASE4
NCT07743684	ACTIVE_NOT_RECRUITING	Temporomandibular Joint Internal Derangement	Hussein Mohammed Ridha	2026-01-01
NCT07775248	RECRUITING	Osteoarthritis (OA) of the Knee	Henry Ford Health System	2025-02-11	PHASE4
NCT07200544	RECRUITING	Postoperative Pain, Acute; Skin Cancer	University of Oklahoma	2025-10-15	PHASE4
NCT05644496	TERMINATED	Post Operative Pain; Osteoarthritis, Knee	Baptist Health South Florida	2023-03-09	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Meloxicam COX inhibitor

Chemical Structure

Molecular Weight: 351.4